UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Mammalian SWI/SNF Chromatin Remodeling Complexes: Emerging Mechanisms and Therapeutic Strategies

Trends in genetics, 2020-12, Vol.36 (12), p.936-950

2020

Volltextzugriff (PDF)

Spartan/C1orf124, a Reader of PCNA Ubiquitylation and a Regulator of UV-Induced DNA Damage Response

Molecular cell, 2012-06, Vol.46 (5), p.625-635

2012

Volltextzugriff (PDF)

TERRA and hnRNPA1 orchestrate an RPA-to-POT1 switch on telomeric single-stranded DNA

Nature (London), 2011-03, Vol.471 (7339), p.532-536

2011

Volltextzugriff (PDF)

Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma

eLife, 2016-01, Vol.5

2016

Volltextzugriff (PDF)

UvrD Limits the Number and Intensities of RecA-Green Fluorescent Protein Structures in Escherichia coli K-12

Journal of Bacteriology, 2007-04, Vol.189 (7), p.2915-2920

2007

Volltextzugriff (PDF)

XthA (Exonuclease III) regulates loading of RecA onto DNA substrates in log phase Escherichia coli cells

Molecular microbiology, 2008-01, Vol.67 (1), p.88-101

2008

Volltextzugriff (PDF)

Differential requirements of two recA mutants for constitutive SOS expression in Escherichia coli K-12

PloS one, 2008-12, Vol.3 (12), p.e4100-e4100

2008

Volltextzugriff (PDF)

CRL4(Cdt2)-mediated destruction of the histone methyltransferase Set8 prevents premature chromatin compaction in S phase

Molecular cell, 2010-10, Vol.40 (1), p.22

2010

Volltextzugriff (PDF)

UvrD303, a Hyperhelicase Mutant That Antagonizes RecA-Dependent SOS Expression by a Mechanism That Depends on Its C Terminus

Journal of Bacteriology, 2009-03, Vol.191 (5), p.1429-1438

2009

Volltextzugriff (PDF)

Direct Role for Proliferating Cell Nuclear Antigen in Substrate Recognition by the E3 Ubiquitin Ligase CRL4Cdt2

The Journal of biological chemistry, 2012-03, Vol.287 (14), p.11410-11421

2012

Volltextzugriff (PDF)

Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response

Cancer research (Chicago, Ill.), 2016-03, Vol.76 (6), p.1313-1319

2016

Volltextzugriff (PDF)

Correction: Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma

eLife, 2016-07, Vol.5

2016

Volltextzugriff (PDF)

Abstract B21: Identifying mechanisms of resistance to BET bromodomain inhibition

Clinical cancer research, 2015-09, Vol.21 (17_Supplement), p.B21-B21

2015

Volltextzugriff (PDF)

Abstract 1224: Discovery of novel BAF inhibitors for the treatment of transcription factor-driven cancers

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1224-1224

2021

Volltextzugriff (PDF)

Abstract 4891: Discovery of novel biomolecular condensate drug targets in oncology using in silico predictive tools

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.4891-4891

2024

Volltextzugriff (PDF)

Abstract A056: Treatment with dual BRG1/BRM (SMARCA4/2) inhibitor FHD-286 ablates tumor-associated androgen response elements (AREs) in prostate cancer

Molecular cancer therapeutics, 2023-12, Vol.22 (12_Supplement), p.A056-A056

2023

Volltextzugriff (PDF)

Abstract A064: Establishing the cellular and molecular impacts of the dual BRM/BRG1 inhibitor FHD-286 on pre-clinical models of non-small cell lung cancer (NSCLC)

Molecular cancer therapeutics, 2023-12, Vol.22 (12_Supplement), p.A064-A064

2023

Volltextzugriff (PDF)

Abstract 4749: Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.4749-4749

2016

Volltextzugriff (PDF)

Abstract 4749: Bromodomain inhibition of the transcriptional coactivators CBPEP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.4749-4749

2016

Volltextzugriff (PDF)

Abstract 3231: Pharmacological inhibition of the m6A RNA reader, YTHDC1, as a novel approach to targeting biomolecular condensates in cancer

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.3231-3231

2024

Volltextzugriff (PDF)

Abstract 1657: Microfluidics-based screening platform identifies a novel therapeutic approach to targeting EML4-ALK driven cancers

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.1657-1657

2024

Volltextzugriff (PDF)

Abstract B19: Targeting dependencies within apoptotic pathways through inhibition of BET bromodomains

Clinical cancer research, 2017-01, Vol.23 (1_Supplement), p.B19-B19

2017

Volltextzugriff (PDF)

Abstract LB190: Modulation of SPI1 transcriptional program contributes to the preclinical anti-tumor activity of SMARCA4/SMARCA2 ATPase inhibitors in AML

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.LB190-LB190

2022

Volltextzugriff (PDF)

Abstract A20: A leukemic model of acquired resistance to BET inhibition reveals a role for CBP/EP300 bromodomains in the regulation of c-MYC expression

Molecular cancer research, 2015-10, Vol.13 (10_Supplement), p.A20-A20

2015

Volltextzugriff (PDF)

CRL4Cdt2-Mediated Destruction of the Histone Methyltransferase Set8 Prevents Premature Chromatin Compaction in S Phase

Molecular cell, 2010-10, Vol.40 (1), p.22-33

2010

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(26)
Dissertationen
(1)

Sprache

Englisch
(27)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Mammalian SWI/SNF Chromatin Remodeling Complexes: Emerging Mechanisms and Therapeutic Strategies

Spartan/C1orf124, a Reader of PCNA Ubiquitylation and a Regulator of UV-Induced DNA Damage Response

TERRA and hnRNPA1 orchestrate an RPA-to-POT1 switch on telomeric single-stranded DNA

Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma

UvrD Limits the Number and Intensities of RecA-Green Fluorescent Protein Structures in Escherichia coli K-12

XthA (Exonuclease III) regulates loading of RecA onto DNA substrates in log phase Escherichia coli cells

Differential requirements of two recA mutants for constitutive SOS expression in Escherichia coli K-12

CRL4(Cdt2)-mediated destruction of the histone methyltransferase Set8 prevents premature chromatin compaction in S phase

UvrD303, a Hyperhelicase Mutant That Antagonizes RecA-Dependent SOS Expression by a Mechanism That Depends on Its C Terminus

Direct Role for Proliferating Cell Nuclear Antigen in Substrate Recognition by the E3 Ubiquitin Ligase CRL4Cdt2

Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response

Correction: Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma

Abstract B21: Identifying mechanisms of resistance to BET bromodomain inhibition

Abstract 1224: Discovery of novel BAF inhibitors for the treatment of transcription factor-driven cancers

Abstract 4891: Discovery of novel biomolecular condensate drug targets in oncology using in silico predictive tools

Abstract A056: Treatment with dual BRG1/BRM (SMARCA4/2) inhibitor FHD-286 ablates tumor-associated androgen response elements (AREs) in prostate cancer

Abstract A064: Establishing the cellular and molecular impacts of the dual BRM/BRG1 inhibitor FHD-286 on pre-clinical models of non-small cell lung cancer (NSCLC)

Abstract 4749: Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma

Abstract 4749: Bromodomain inhibition of the transcriptional coactivators CBPEP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma

Abstract 3231: Pharmacological inhibition of the m6A RNA reader, YTHDC1, as a novel approach to targeting biomolecular condensates in cancer

Abstract 1657: Microfluidics-based screening platform identifies a novel therapeutic approach to targeting EML4-ALK driven cancers

Abstract B19: Targeting dependencies within apoptotic pathways through inhibition of BET bromodomains

Abstract LB190: Modulation of SPI1 transcriptional program contributes to the preclinical anti-tumor activity of SMARCA4/SMARCA2 ATPase inhibitors in AML

Abstract A20: A leukemic model of acquired resistance to BET inhibition reveals a role for CBP/EP300 bromodomains in the regulation of c-MYC expression

CRL4Cdt2-Mediated Destruction of the Histone Methyltransferase Set8 Prevents Premature Chromatin Compaction in S Phase

Suchergebnisse filtern